0001104659-22-075798.txt : 20220629 0001104659-22-075798.hdr.sgml : 20220629 20220629161205 ACCESSION NUMBER: 0001104659-22-075798 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220629 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220629 DATE AS OF CHANGE: 20220629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 221054798 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 8-K 1 tm2220042d1_8k.htm FORM 8-K
0001012477 false 0001012477 2022-06-29 2022-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 29, 2022

 

 

 

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

 

 

 

Ireland 001-37977 98-1341933
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

10 Earlsfort Terrace

Dublin 2, Ireland, D02 T380

 

Not Applicable

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +353 1 920 1000

 

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered

American Depositary Shares*

Ordinary Shares, nominal value $0.01 per share**

AVDL

N/A

 The Nasdaq Global Market

 

*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) Ordinary Share.

 

 

** Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

Item 2.05. Costs Associated with Exit or Disposal Activities.

 

On June 29, 2022, Avadel Pharmaceuticals plc (the “Company”) announced cost structure optimization efforts to reduce quarterly cash operating expenses. The reduction in cash operating expenses, together with cash, cash equivalents and marketable securities currently on hand, is expected to extend the Company’s cash runway to a potential final approval of its New Drug Application for FT218, which could occur in June 2023 or possibly sooner. The cost structure optimization will include a nearly 50% reduction in the Company’s workforce. The workforce reduction will be completed by the end of August 2022.

 

As a result of the cost structure optimization efforts, the Company expects to record an aggregate restructuring charge of between $3.0 to $4.0 million, comprised primarily of severance related costs, in the second quarter of 2022. The Company estimates that the cost structure optimization will reduce total recurring quarterly cash operating expenses to between $12.0 to $14.0 million, excluding inventory purchases. These estimates of the restructuring costs that the Company expects to incur and potential operating expense reductions, and the timing thereof, are subject to a number of assumptions and actual results may differ.

 

Item 8.01. Other Events.

 

On June 29, 2022, the Company issued a press release titled “Avadel Pharmaceuticals Provides Corporate Update.” A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

   

Exhibit No.     Description  

99.1 

  

Press release issued by Avadel Pharmaceuticals plc on June 29, 2022 

104   Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

Cautionary Note Regarding Forward-Looking Statements

 

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to the Company’s future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to, expectations regarding the timing and results of the Company’s cost structure optimization efforts; the estimated charges and costs expected to be incurred in connection with such cost structure optimization efforts; and the projected cost savings resulting from the Company’s cost structure optimization efforts; the FDA’s tentative and/or full approval of the FT218 NDA, if at all; the commercial launch of FT218, if approved; the potential therapeutic benefit of FT218; and, assuming commercial availability, the potential market opportunity for and anticipated financial performance of FT218.

 

Any forward-looking statements in this Current Report on Form 8-K are based on estimates and assumptions that are made within the bounds of the Company’s knowledge of its business and operations and that it considers reasonable. However, the Company’s business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the Company’s business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in the Company’s forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission (SEC) on March 16, 2022, and subsequent SEC filings.

 

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 29, 2022 AVADEL PHARMACEUTICALS PLC
   
  By:   /s/ Jerad G. Seurer           
    Name: Jerad G. Seurer
    Title: General Counsel & Corporate Secretary

 

 

 

 EX-99.1 2 tm2220042d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Avadel Pharmaceuticals Provides Corporate Update

 

-    Pursuing strategies to accelerate final approval of FT218 NDA

 

-    Optimizing cost structure to fund strategic priorities and extend cash runway

 

-    Continuing key activities to accelerate launch timing of FT218, targeting multi-billion-dollar narcolepsy market opportunity

 

-    Management to host a conference call tomorrow, June 30 at 8:00 a.m. ET

 

DUBLIN, Ireland, June 29, 2022 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the steps it is taking to explore every available pathway to accelerate the decision by the U.S. Food and Drug Administration (FDA) to grant final approval of its lead drug candidate, FT218, prior to June 2023. Concurrent with this strategy, Avadel has received and agreed upon what is expected to be a final label and is completing the last edits of the Risk Evaluation and Mitigation Strategy (“REMS”) with FDA and expects to receive tentative approval of FT218.

 

“We believe the receipt of a tentative approval for the FT218 New Drug Application (NDA) will validate the clinical efficacy and safety profile of FT218 for people living with narcolepsy and will provide clarity on the timing and pathway to a potential final approval and subsequent commercial launch. Nearly every day we hear from disappointed patients who are waiting for a once at bedtime oxybate treatment option. We believe FT218 has a clear and meaningful place in the multi-billion-dollar narcolepsy market and will continue to pursue every potential option to make it available as soon as possible to all eligible patients whose lives it has the potential to improve,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. “As part of these efforts, we are optimizing our cost structure by focusing our existing resources on our most important priorities, thus extending our cash runway and subsequent financial bridge to a potential final approval in June 2023 or sooner.”

 

Avadel, in alignment with our most important priorities, is taking the following actions, including those that can potentially accelerate FDA’s final approval decision and shorten the timeline between approval and launch of FT218:

 

-Submitted a Paragraph IV patent certification and expects to receive a tentative approval.

 

-Filed a motion in the U.S. District Court of Delaware to delist US Patent No. 8,731,963 (the “REMS patent”), from FDA’s Orange Book. A court order requiring the patent holder to delist the REMS patent from the Orange Book could provide a pathway for a final approval of FT218 prior to June 2023.

 

-Preparing for a claim construction hearing (“Markman hearing”) in the existing patent litigation in the U.S. District Court of Delaware which is scheduled for August 31, 2022. The Court has previously stated this claim construction hearing needs to take place prior to ruling on the motion to delist the REMS patent from the Orange Book.

 

 

 

 

 

 

-Investing in patient and physician education including the Company’s disease state program, www.narcolepsydisrupts.com, which has resulted in over 5,000 narcolepsy patient enrollments in the first half of 2022.

 

-Continuing key activities in anticipation of a final approval on or before June 2023, including planning for the final preparation of the FT218 REMS program and the continued manufacturing of commercial supply.

 

-Optimizing the cost structure to reduce total quarterly cash operating expenses to $12.0 to $14.0 million, excluding inventory purchases. A restructuring charge of between $3.0 - $4.0 million, comprised primarily of severance related costs associated with a nearly 50% reduction in workforce, is expected to be recorded in the second quarter of 2022. The Company expects to report greater than $100.0 million of cash, cash equivalents and marketable securities as of June 30, 2022.

 

Based on extensive market research and comprehensive claims data analytics, Avadel estimates the total patient population could be in the range of approximately 30,000-35,000 and expects FT218, if approved, to be the treatment of choice for patients suffering from narcolepsy-related excessive daytime sleepiness (EDS) or cataplexy. The current twice-nightly U.S. narcolepsy oxybate market is estimated at $1.8 billion comprised of approximately 16,000 patients. In addition, Avadel estimates that in the last three years, 10,000 – 15,000 patients have discontinued their twice-nightly oxybate use, many due to the complications associated with the middle of the night dosing. Furthermore, based on an analysis of U.S. claims data, the Company believes that each year approximately 3,000 patients initiate oxybate treatment for the first time and expects this to grow by 25-50% over time with the introduction of FT218. Based on the estimated total patient population, the potential market opportunity could be in excess of $3.0 billion annually.

 

Conference Call

 

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 4176205. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

 

About FT218

 

FT218 is an investigational formulation of sodium oxybate leveraging the Company’s proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of EDS or cataplexy in adults with narcolepsy.

 

In March 2020, Avadel completed the REST-ON trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in adults with narcolepsy. Among the three co-primary endpoints, FT218 demonstrated statistically significant and clinically meaningful results in EDS, the clinician’s overall assessment of the patient’s functioning, and reduction in cataplexy attacks for all three evaluated doses compared to placebo.

 

In January 2018, the FDA granted FT218 Orphan Drug Designation for the treatment of narcolepsy based on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for those with narcolepsy due to the consequences of middle-of-the-night dosing of the approved product. The NDA for FT218 is currently under review by the FDA.

 

 

 

 

 

 

Avadel is currently evaluating the long-term safety and tolerability of FT218 in the open-label RESTORE clinical study. For more information, visit: www.restore-narcolepsy-study.com.

 

About Avadel Pharmaceuticals plc

 

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging its proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

 

Cautionary Disclosure Regarding Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to the Company’s future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but are not limited to: expectations regarding the FDA’s tentative and/or full approval of the FT218 NDA; the commercial launch of FT218, if approved; the potential therapeutic benefit of FT218; the timing and results of the Company’s cost structure optimization efforts; the estimated charges and costs expected to be incurred in connection with such cost structure optimization efforts; the projected cost savings resulting from the Company’s cost structure optimization efforts; and, if approved, the potential market opportunity for FT218. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project,” “next steps” and similar expressions, and the negatives thereof (if applicable).

 

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, which we filed with the Securities and Exchange Commission on March 16, 2022, and subsequent SEC filings.

 

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

 

 

 

 

 

 

Investor Contact:

Courtney Turiano

Stern IR, Inc.

courtney.turiano@sternir.com

(212) 698-8687

 

Media Contact:

Nicole Raisch Goelz

Real Chemistry

ngoelz@realchemistry.com

(408) 568-4292

 

Brandi Robinson

Avadel Pharmaceuticals

brobinson@avadel.com

(636) 383-4302

 

 

 

 EX-101.SCH 3 avdl-20220629.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avdl-20220629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avdl-20220629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2220042d1_ex99-1img001.jpg GRAPHIC begin 644 tm2220042d1_ex99-1img001.jpg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end GRAPHIC 7 tm2220042d1_ex99-1img002.jpg GRAPHIC begin 644 tm2220042d1_ex99-1img002.jpg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end GRAPHIC 8 tm2220042d1_ex99-1img003.jpg GRAPHIC begin 644 tm2220042d1_ex99-1img003.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Jun. 29, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 29, 2022
Entity File Number 001-37977
Entity Registrant Name AVADEL PHARMACEUTICALS PLC
Entity Central Index Key 0001012477
Entity Tax Identification Number 98-1341933
Entity Incorporation, State or Country Code L2
Entity Address, Address Line One 10 Earlsfort Terrace
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code D02 T380
City Area Code 353
Local Phone Number 1 920 1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares*
Trading Symbol AVDL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 tm2220042d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001012477 2022-06-29 2022-06-29 iso4217:USD shares iso4217:USD shares 0001012477 false 8-K 2022-06-29 AVADEL PHARMACEUTICALS PLC L2 001-37977 98-1341933 10 Earlsfort Terrace Dublin 2 IE D02 T380 353 1 920 1000 false false false false American Depositary Shares* AVDL NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( (*!W50'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " ""@=U4PH$N$>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R'&A,)/ZLK%3"X,5-G8SMMJ:Q;&Q-9*^_9RL31G; ^QHZ?>G M3Z#61&E"PN<4(B9RF.]&W_59FKAA)Z(H ;(YH=>Y+HF^- \A>4WEF8X0M?G0 M1P3!^1H\DK::-$S *BY$IEIKI$FH*:0+WIH%'S]3-\.L >S08T\9FKH!IJ:) M\3QV+=P $XPP^?Q=0+L0Y^J?V+D#[)(-MM7^9U*]=G MTKW!\BL[2>>(&W:=_+IZ>-P_,26X$!5?5^)^+[ALA.3-^^3ZP^\F[(-U!_>/ MC:^"JH5?=Z&^ %!+ P04 " ""@=U4F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M (*!W50W+4!\2@0 'D0 8 >&PO=V]R:W-H965T&UL MG9C1]V(F9#.H)>?F^E!3Z4V$I+/-#%I'#/] M>LLCM>T[U'D[\2C6&YN=: QZ"5OS.;=?DIF&5J-0"47,I1%*$LU7?<>G-[=> M*PO(>SP)OC4'QR1[E*52W[+&).P[;D;$(Q[83(+!SS,?\BC*E(#C^U[4*>Z9 M!1X>OZG?Y0\/#[-DA@]5]%6$=M-W.@X)^8JED7U4VX]\_T!7F5Z@(I-_D^VN M;ZOED" U5L7[8""(A=S]LI=](@X"O.Z1 &\?X.7H M90?YH^;1 "=D-BISJ^&J@#@[&*IGKGL-"U+9B4:P#[O=A7E'POY(Y27QNN?$ MN?B$0+0*B!:JX@-!F%/< M16Q=18''KUAD.,)Q57!![Y6F25#3E[8'%EHG =_\D? MC:=D]M%_O/>'XR^+R="?SLEL.D0@.P5DYQ3((0RI9A&9R)"_D$_\M0H35W(A M=R[U6FCNN@56]Q2L!7LADQ#8Q$H$++?RXR.+*W8[%[39HMUF$\&C;FF=[BF M$QDHG2B=LYV3N857@2A-ABJ%A$)>55@YXC7J4^Q]H ?^3D^!],,07-&!S&%,Y.U#WDPE%RY4-[73O#G(_]/C*ET>.\DAQ_#(*RS+/T."G:3F4;" M9/5P_L^-0.-@(YEMRN]9=D=#(KX"(?>R#5:M=_O<7<.J)-];+I6%G6I^N.$, MRC_K -=72MFW1K9=+?YM&/P+4$L#!!0 ( (*!W52?H!OPL0( .(, - M >&PO9KEMWDOSAR+DCO9*ZW="C M<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+ M#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\ M0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9 M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I: M*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#S MGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[ MBK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1 MS;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG M_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P M%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/ MK O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( (*!W527 MBKL

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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avadel.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2220042d1_8k.htm avdl-20220629.xsd avdl-20220629_lab.xml avdl-20220629_pre.xml tm2220042d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2220042d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2220042d1_8k.htm" ] }, "labelLink": { "local": [ "avdl-20220629_lab.xml" ] }, "presentationLink": { "local": [ "avdl-20220629_pre.xml" ] }, "schema": { "local": [ "avdl-20220629.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avdl", "nsuri": "http://avadel.com/20220629", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2220042d1_8k.htm", "contextRef": "From2022-06-29to2022-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://avadel.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2220042d1_8k.htm", "contextRef": "From2022-06-29to2022-06-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avadel.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-075798-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-075798-xbrl.zip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end